Literature DB >> 6600790

Inactivation of cytochrome P-450 by a troleandomycin metabolite. Protective role of glutathione.

D Pessayre, M Tinel, D Larrey, B Cobert, C Funck-Brentano, G Babany.   

Abstract

Troleandomycin, a macrolide antibiotic, has been shown to be demethylated and oxidized into a metabolite which forms an inactive complex with the iron(II) of cytochrome P-450. The role of glutathione in the metabolism of troleandomycin was investigated. Administration of troleandomycin (1 mmol X kg-1 p.o.) decreased the concentration of glutathione in the liver. The depletion of glutathione was increased in rats pretreated with phenobarbital and decreased in rats pretreated with CoCl2. In vitro, an inverse relationship was found between the concentration of glutathione in the incubation mixture and the appearance of the cytochrome P-450-troleandomycin metabolite complex. Glutathione, however, did not inhibit the demethylation of troleandomycin and did not destroy the cytochrome P-450-troleandomycin metabolite complex. The in vitro protective effect of glutathione was reproduced by cysteine but not by glycine. In vivo, decreasing the concentration of glutathione in the liver by food deprivation or by the administration of diethylmaleate increased the formation of the cytochrome P-450-troleandomycin metabolite complex. These results indicate that glutathione is depleted by a troleandomycin metabolite in vivo, whereas glutathione protects against the formation of the inactive cytochrome P-450-troleandomycin metabolite complex in vitro and in vivo.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6600790

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  7 in total

1.  Identification of human liver cytochrome P450 isoforms mediating secondary omeprazole metabolism.

Authors:  T Andersson; J O Miners; M E Veronese; D J Birkett
Journal:  Br J Clin Pharmacol       Date:  1994-06       Impact factor: 4.335

2.  Diazepam metabolism by human liver microsomes is mediated by both S-mephenytoin hydroxylase and CYP3A isoforms.

Authors:  T Andersson; J O Miners; M E Veronese; D J Birkett
Journal:  Br J Clin Pharmacol       Date:  1994-08       Impact factor: 4.335

Review 3.  The role of metabolites in predicting drug-drug interactions: focus on irreversible cytochrome P450 inhibition.

Authors:  Brooke M VandenBrink; Nina Isoherranen
Journal:  Curr Opin Drug Discov Devel       Date:  2010-01

Review 4.  Pharmacokinetic interactions of the macrolide antibiotics.

Authors:  T M Ludden
Journal:  Clin Pharmacokinet       Date:  1985 Jan-Feb       Impact factor: 6.447

5.  Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism.

Authors:  T Andersson; J O Miners; M E Veronese; W Tassaneeyakul; W Tassaneeyakul; U A Meyer; D J Birkett
Journal:  Br J Clin Pharmacol       Date:  1993-12       Impact factor: 4.335

Review 6.  Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs.

Authors:  Shufeng Zhou; Sui Yung Chan; Boon Cher Goh; Eli Chan; Wei Duan; Min Huang; Howard L McLeod
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 5.577

7.  Clinical outcomes and management of mechanism-based inhibition of cytochrome P450 3A4.

Authors:  Shufeng Zhou; Eli Chan; Xiaotian Li; Min Huang
Journal:  Ther Clin Risk Manag       Date:  2005-03       Impact factor: 2.423

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.